ES2146404T3 - Vector de expresion de adenovirus hepatoespecifico. - Google Patents

Vector de expresion de adenovirus hepatoespecifico.

Info

Publication number
ES2146404T3
ES2146404T3 ES96923829T ES96923829T ES2146404T3 ES 2146404 T3 ES2146404 T3 ES 2146404T3 ES 96923829 T ES96923829 T ES 96923829T ES 96923829 T ES96923829 T ES 96923829T ES 2146404 T3 ES2146404 T3 ES 2146404T3
Authority
ES
Spain
Prior art keywords
pct
liver
vector
promoter
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923829T
Other languages
English (en)
Inventor
Volker Sandig
Peter Loser
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2146404T3 publication Critical patent/ES2146404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UN VECTOR DE ADENOVIRUS PARA LA TERAPIA GENICA HEPATICA; LOS CAMPOS DE APLICACION SON LA MEDICINA Y EL TRATAMIENTO DE DEFECTOS GENETICOS Y ENFERMEDADES TUMORALES DEL HIGADO Y LA BIOLOGIA MOLECULAR. EL VECTOR SEGUN LA INVENCION SE CARACTERIZA PORQUE SE INJERTA EN EL GENOMA DEL ADENOVIRUS UN GEN TERAPEUTICO, QUE ESTA ACOPLADO A UN PROMOTOR HEPATO ESPECIFICO QUE CONSISTE EN UNOS ELEMENTOS INTENSIFICADORES DEL VIRUS DE LA HEPATITIS B Y UN PROMOTOR MINIMO SIN INTENSIFICADOR Y OPCIONALMENTE RODEADO DE ELEMENTOS SAR.
ES96923829T 1995-07-15 1996-07-08 Vector de expresion de adenovirus hepatoespecifico. Expired - Lifetime ES2146404T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525900A DE19525900C1 (de) 1995-07-15 1995-07-15 Leberspezifischer Adenovirus-Expressionsvektor

Publications (1)

Publication Number Publication Date
ES2146404T3 true ES2146404T3 (es) 2000-08-01

Family

ID=7766966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96923829T Expired - Lifetime ES2146404T3 (es) 1995-07-15 1996-07-08 Vector de expresion de adenovirus hepatoespecifico.

Country Status (8)

Country Link
US (1) US6025195A (es)
EP (1) EP0839205B1 (es)
JP (1) JPH11509412A (es)
AT (1) ATE189481T1 (es)
CA (1) CA2226926A1 (es)
DE (2) DE19525900C1 (es)
ES (1) ES2146404T3 (es)
WO (1) WO1997004117A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059063A2 (en) * 1997-06-23 1998-12-30 University Of Saskatchewan Bovine adenovirus type 3 genome
CN1593133B (zh) * 1998-06-16 2010-12-08 巴斯福股份公司 具有增效效果的除草混合物
DE60013586T2 (de) 1999-04-02 2005-02-03 Hisamitsu Pharmaceutical Co., Inc., Tosu Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
AU5802200A (en) * 1999-04-30 2000-11-17 Karsten Brand Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
ES2284545T3 (es) * 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
AU2002237910B2 (en) * 2001-01-22 2007-01-25 Biogen Idec Ma Inc. Method of enhancing delivery of a therapeutic nucleic acid
DE10109780A1 (de) * 2001-02-28 2002-09-05 Cardion Ag Episomale Vektoren enthaltend Matrix-Anheftungsregionen zur zellspezifischen Genexpression
GB0206357D0 (en) * 2002-03-18 2002-05-01 Univ Bath Cells
EP2747551B1 (en) 2011-08-26 2020-02-12 Yecuris Corporation Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
US20190256867A1 (en) 2018-02-01 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
GB201900741D0 (en) * 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5457294A (en) * 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system

Also Published As

Publication number Publication date
CA2226926A1 (en) 1997-02-06
EP0839205A1 (de) 1998-05-06
DE19525900C1 (de) 1996-12-12
US6025195A (en) 2000-02-15
DE59604375D1 (de) 2000-03-09
ATE189481T1 (de) 2000-02-15
EP0839205B1 (de) 2000-02-02
JPH11509412A (ja) 1999-08-24
WO1997004117A1 (de) 1997-02-06

Similar Documents

Publication Publication Date Title
ES2146404T3 (es) Vector de expresion de adenovirus hepatoespecifico.
ATE282434T1 (de) Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor
Nakamura et al. Reciprocal modulation of growth and liver functions of mature rat hepatocytes in primary culture by an extract of hepatic plasma membranes.
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
ATE317895T1 (de) Vektoren zur gewebsspezifischen replikation
ATE331800T1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
ATE352634T1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
ATE324442T1 (de) Varianten des p53-proteins und deren therapeutischen verwendungen
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE234362T1 (de) Konditionell-replizierende virale vektoren und ihre verwendung.
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
DK1032429T3 (da) Fremgangsmåde til DNA-afgivelse in vivo ved anvendelse af et nålefrit apparatur
Cervello et al. Expression of HIP/PAP mRNA in human hepatoma cell lines
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
Adolf et al. Effects of butyrate on induction and action of interferon
Sakamoto et al. Selective and enhanced transgene expression in hepatocellular carcinoma cells by asialofetuin-labelled liposomes and AFP promoter
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
WO2002038188A3 (de) Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 839205

Country of ref document: ES